Prosthesis (i.e. – artificial body members) – parts thereof – or ai – Heart valve – Having rigid or semirigid pivoting occluder
Patent
1997-01-17
1998-12-01
Willse, David H.
Prosthesis (i.e., artificial body members), parts thereof, or ai
Heart valve
Having rigid or semirigid pivoting occluder
8 9411, A61F 224, B01C 300
Patent
active
058431810
ABSTRACT:
Disclosed is a controlled autolysis method for making biological tissue substantially acellular by exposing the biological material, prior to any fixation thereof, to at least one buffered solution having a pH in the range from about 5.0 to 8.0 and a temperature in the range from about 12.degree. C. to 30.degree. C. for a sufficient period of time to render at least one region of the biological material substantially acellular while substantially preserving the structural integrity and non-cellular structural components of the biological material. Also disclosed is a method of making a bioprosthetic heart valve using biological material that has been treated by controlled autolysis and a method of treating a mammal having a defective heart valve using a bioprosthetic heart valve made, in part, by controlled autolysis.
REFERENCES:
patent: 4050893 (1977-09-01), Hancock
patent: 4083066 (1978-04-01), Schmitz et al.
patent: 4120649 (1978-10-01), Schechter
patent: 4239492 (1980-12-01), Holman et al.
patent: 4323358 (1982-04-01), Lentz et al.
patent: 4378224 (1983-03-01), Nimni et al.
patent: 4383832 (1983-05-01), Fraefel et al.
patent: 4402697 (1983-09-01), Pollock et al.
patent: 4405327 (1983-09-01), Pollock
patent: 4553974 (1985-11-01), Dewanjee
patent: 4647283 (1987-03-01), Carpentier et al.
patent: 4648881 (1987-03-01), Carpentier et al.
patent: 4704131 (1987-11-01), Noishiki et al.
patent: 4729139 (1988-03-01), Nashef
patent: 4770665 (1988-09-01), Nashef
patent: 4776853 (1988-10-01), Klement et al.
patent: 4786287 (1988-11-01), Nashef et al.
patent: 4798611 (1989-01-01), Freeman, Jr.
patent: 4800603 (1989-01-01), Jaffe
patent: 4801299 (1989-01-01), Brendel et al.
patent: 4838888 (1989-06-01), Nashef
patent: 4885005 (1989-12-01), Nashef et al.
patent: 4976733 (1990-12-01), Girardot
patent: 4996054 (1991-02-01), Pietsch et al.
patent: 5002566 (1991-03-01), Carpentier et al.
patent: 5094661 (1992-03-01), Levy et al.
patent: 5104405 (1992-04-01), Nimni
patent: 5145771 (1992-09-01), Lemasters et al.
patent: 5192312 (1993-03-01), Orton
patent: 5215541 (1993-06-01), Nashef et al.
patent: 5336616 (1994-08-01), Livesay et al.
patent: 5397353 (1995-03-01), Oliver et al.
patent: 5595571 (1997-01-01), Jaffe et al.
"Damage of Porcine Aortic Valve Tissue Caused by the Surfactant Sodiumdodecylsulphat," Bodnar, et al., Thorac, Cardiovasc. Surgeon, vol. 2, pp.. 82-85, 1986.
"Degeneration and Calcification of Bioprosthetic Cardiac Valves," Bioprosthetic Tricuspid Valve Implantation in Sheep, Barnhart, et al., Animal Model of Human Diseases, pp. 136-139.
"Techniques for Prevention of Calcification of Valvular Bioprostheses," Carpentier, et al., Valvular Heart Disease, vol. 70 (Suppl I), Sep. 1984.
"Possible Causes for the Calcification of Glutaraldehyde-Treated Tissue Heart Valves and Blkiood Contacting Elastomers During Prolonged Use in Medical Devices: A Physicochemical View," S.D. Bruck, Biomaterials, vol. 2, 1981.
"Treatment of Tissues or Ogans (e.g. pig heart valves) Used for Animal or Human Transplant," Glick et al., Derwent Publications Ltd., 1 page, 1988.
"Calcific Deposits in Porcine Bioprostheses: Structure and Pathogenesis," Ferrans et al., The American Journal of Cardiology, vol. 46, 1980.
"The Cryopreserved Homograft Valve in the Pulmnary Position: Mid-Term Results and Technical Consideration," Lamberti, et al., Journal of Cardiac Surgery, vol. 6, No. 4, Supplement, pp. 627-632, 1991.
"Aortic Valve Allografts for Mitral Valve Replacement," Stinson, et al., Surgery, vol. 77, No. 6, pp. 861-867, Jun. 1975.
"Calcification of Glutaraldehyde-Preserved Porcine Xenografts in Young Patients," Curcio et al., J. Thorac, Cardiovasc. Surgery, vol. 81, pp. 621-625, 1981.
"Calcification of Glutaraldehyde-Preserved Porcine and Bovin Xenograft valves in Young Children," Fiddler et al., The Annals of Thoractice Surgery, vol. 35, No. 3, pp. 257-261, Mar. 1983.
"A Study of the Cells in the Explanted Viable Cryopreserved Allograft Valve," O'Brien et al., Journal of Cardiac Surgery, vol. 3, pp. 279-287, Supplement, 1988.
"Calcific Stenosis of the Porcine Heterograft," Lamberti et al., The Annals of Thoracic Surgery, vol. 28, No. 1, pp. 28-32, 1979.
"Calification in Porcine Xenograft Valves in Children," Silver et al., The American Journal of Cardiology, vol. 45, pp. 685-689, Mar. 1980.
"Calcification of Porcine Prosthetic Heart valves: A Radiographic and Light Microscopic Study," Cipriano et al., Circulation, vol. 66, No. 5, pp. 1100-1104, Nov. 1982.
"Marked Thrombosis and Calcification of Porcine Heterograft Valves," Platt et al., Circulation, vol. 62, No. 4, pp. 862-869, oct. 1980.
"Durability of the Viable Aortic Allograft," Angell et al., J. Thorac. Cardiovasc. Surg.. vol. 98, pp. 48-56, 1989.
Hancock Warren D.
Jaffe Norman
Hancock Jaffe Laboratories
Willse David H.
LandOfFree
Biological material pre-fixation treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biological material pre-fixation treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biological material pre-fixation treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2392114